Eric Mansfield, MD
Otolaryngology · Fayetteville, NCNPI 1679544829
Payments from drug & device makers
Across 413 payments — averaging $43.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$890
- Medtronic$738
- Stryker$393
- plus $3K from 31 others
What the payments were for
- Consulting fees$5506%
- Food & beverage$7,86291%
- Education$1932%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 61 | $10,531 |
| GSK | 114 | $1,422 |
| Regeneron Healthcare Solutions, Inc. | 47 | $1,379 |
| Sanofi | 38 | $890 |
| Medtronic(2 entities) | 7 | $738 |
| Stryker | 13 | $393 |
| Optinose US, Inc. | 22 | $357 |
| Hologic Sales And Service, LLC | 3 | $198 |
| Acclarent, Inc | 4 | $196 |
| Novartis | 9 | $158 |
| Intersect ENT, Inc. | 6 | $140 |
| Genentech USA, Inc. | 9 | $134 |
| Hikma Pharmaceuticals USA | 7 | $129 |
| Amgen | 8 | $128 |
| Smith+Nephew | 5 | $118 |
| Alk-abello, Inc | 6 | $110 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $108 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Integra Lifesciences Corporation | 2 | $83 |
| Aerin Medical Inc. | 5 | $82 |
| Phadia US Inc. | 4 | $78 |
| AbbVie | 4 | $73 |
| Acelrx Pharmaceuticals, Inc. | 5 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $71 |
| Grifols USA, LLC | 2 | $66 |
| Aytu Biopharma, Inc. | 4 | $61 |
| Pfizer | 3 | $47 |
| Merck | 2 | $45 |
| Biohaven Pharmaceuticals, Inc. | 2 | $38 |
| Shire North American Group Inc | 2 | $37 |
| Forte Bio-pharma LLC | 1 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Organon | 2 | $22 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUVENT$550
- PROPEL$147
- CoolSeal Generator$129
How this compares
$18,108 in reported general payments places this provider in the 90th percentile of 362 otolaryngology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 32 | $131,236 |
| XolairOmalizumab | 14 | $116,578 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $54,531 |
| NucalaMepolizumab | 12 | $41,233 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $17,432 |
| VoqueznaVonoprazan Fumarate | 20 | $15,482 |
| Olopatadine Hcl | 158 | $14,888 |
| XhanceFluticasone Propionate | 11 | $6,542 |
| Cevimeline Hcl | 49 | $6,209 |
| Ipratropium Bromide | 188 | $4,641 |
| Azelastine Hcl | 116 | $4,357 |
| DuleraMometasone/Formoterol | 12 | $4,245 |
| Famotidine | 383 | $3,818 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 30 | $3,816 |
| Epinephrine | 21 | $3,528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala | $1,422 | $95,76497 claims |
| AstraZenecaBreztri Aerosphere | $10,531 | $17,43225 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $7 | $15,48220 claims |
| Optinose US, Inc.Xhance | $357 | $6,54211 claims |
| MerckDulera | $45 | $4,24512 claims |
| Hikma Pharmaceuticals USAEpinephrine | $129 | $3,52821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 362 otolaryngology providers in North Carolina.
Other otolaryngology in Fayetteville
- Robert FerrisRaleigh$2.5M
- David JangDurham$1M
- Mark WeigelHuntersville$275K
- Stephen PottsWinston Salem$242K
- Adam ZanationHickory$227K
- Anne SelleckChapel Hill$165K
- Jonathan MossMatthews$164K
- William ScurryWinston Salem$162K
- James MimsWinston Salem$114K
- Stephen HarperWinston Salem$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.